🧪
hypothesis

SIRPA-Mediated Microglial Disinhibition

Hypothesis

SIRPA-Mediated Microglial Disinhibition

SIRPA antagonism to enhance microglial activation through removal of inhibitory CD47-SIRPA signaling.
🧬 ['SIRPA']🩺 neurodegeneration🎯 Composite 48%💱 $0.56▼8.2%active
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite48%

🧪 Overview

SIRPA antagonism to enhance microglial activation through removal of inhibitory CD47-SIRPA signaling

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["CD47 Expression on Neurons and Plaques<br/>Anti-Phagocytic Do Not Eat Me Signal"]
    B["SIRPA Receptor on Microglia<br/>Inhibitory Immunoreceptor"]
    C["CD47-SIRPA Interaction<br/>Microglial Phagocytosis Suppressed"]
    D["Amyloid and Debris Accumulate<br/>Clearance Impaired in Disease"]
    E["SIRPA Antagonist Treatment<br/>Removes CD47-Mediated Inhibition"]
    F["Microglial Phagocytic Activation<br/>Disinhibition of Clearance"]
    G["Amyloid Plaque Burden Reduced<br/>Neuroinflammation Resolved"]
    H["AD Neuroprotective Outcome<br/>Cognitive Preservation"]
    A --> B
    B --> C
    C --> D
    E -.->|"blocks inhibitory signal"| C
    E --> F
    F --> G
    G --> H
    style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix5 supports0 contradicts
Supports
Microglia regulation of synaptic plasticity and learning and memory.
Neural Regen Res2022PMID:34472455medium
Supports
Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation.
J Clin Invest2024PMID:39545414medium
Supports
CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development.
Neuron2018PMID:30308165medium
Supports
CD47 signaling induces hepatic cell death and microglia activation during hepatic encephalopathy.
Metab Brain Dis2024PMID:39656327medium
Supports
Engineered Bacterial Outer Membrane Vesicles-Based Doxorubicin and CD47-siRNA Co-Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma.
Adv Mater2025PMID:40035513medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — ['SIRPA']

No curated PDB or AlphaFold mapping for ['SIRPA'] yet. Search RCSB →

💉 Clinical Trials (1)

0
Active
0
Completed
0
Total Enrolled
Untitled TrialUnknown
Unknown·

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ['SIRPA'] →

No DepMap CRISPR Chronos data found for ['SIRPA'].

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0580
Events (7d)
1
Price History
▼8.2%

💾 Resource Usage

LLM Tokens
14,692
$0.0882
Total Cost
$0.0882

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF anti-SIRPA antibody (10 mg/kg, i.p., every 3 days) is administered to 5xFAD transgenic mice for 4 weeks, THEN amyloid plaque burden will decrease by ≥30% in the hippocampus compared to vehicle-treaCongo red+ plaque area decreases ≥30% in hippocampus; Iba1+ microglia show hypertrophic morphology (somatic area ≥150% of control); CD68+ microglial coverage ar— no observation —pending0.72
IF primary mouse microglia are treated with SIRPA-blocking antibody (500 µg/mL) for 48 hours, THEN cell surface CD86 and CD68 expression will increase by ≥50% compared to isotype control, using culturCD86 MFI increases from baseline ~200 to ≥300; CD68+ area increases ≥50% via confocal morphometry; phagocytosis of fluorescent E. coli bioparticles increases ≥4— no observation —pending0.78
🔮 Falsifiable Predictions (2)
pendingconf 78%
IF primary mouse microglia are treated with SIRPA-blocking antibody (500 µg/mL) for 48 hours, THEN cell surface CD86 and CD68 expression will increase by ≥50% compared to isotype control, using cultured primary microglia from C57BL/6 mice.
Predicted outcome: CD86 MFI increases from baseline ~200 to ≥300; CD68+ area increases ≥50% via confocal morphometry; phagocytosis of fluorescent E. coli bioparticles in
Falsification: No significant change (<20% increase) in CD68/CD86 expression or phagocytic index after SIRPA blockade would refute the hypothesis that SIRPA antagonism disinhibits microglial activation
pendingconf 72%
IF anti-SIRPA antibody (10 mg/kg, i.p., every 3 days) is administered to 5xFAD transgenic mice for 4 weeks, THEN amyloid plaque burden will decrease by ≥30% in the hippocampus compared to vehicle-treated controls, using 5xFAD APP/PS1 mice at 6 months of age.
Predicted outcome: Congo red+ plaque area decreases ≥30% in hippocampus; Iba1+ microglia show hypertrophic morphology (somatic area ≥150% of control); CD68+ microglial c
Falsification: No reduction in amyloid burden or failure to observe morphologically activated microglia after SIRPA antagonist treatment would disprove the hypothesis that SIRPA blockade enhances microglial-mediated
View on SciDEX ↗